SciELO - Scientific Electronic Library Online

vol.45 issue5Prevalence and types of drug interactions in hospitalized pediatric patients in Mexico CityApplication of the CMO methodology to the improvement of primary adherence to concomitant medication in people living with-HIV. The PRICMO Project author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343


MARIN-JIMENEZ, Ignacio; CARRASCOSA, José Manuel; GUIGINI, Marcelo Alejandro  and  MONTE-BOQUET, Emilio. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: a national survey. Farm Hosp. [online]. 2021, vol.45, n.5, pp.240-246.  Epub Jan 16, 2023. ISSN 2171-8695.


To analyze knowledge, perceptions, attitude, barriers and facilitators of biosimilars uptake across physicians managing immune diseases and hospital pharmacists.


Two structured and closed anonymous online surveys were designed and sent to 41 physicians (rheumatologists, dermatologists, gastroenterologists) and 32 hospital pharmacists. Sociodemographic and clinical practice related variables were collected. We also gathered information about biosimilars knowledge and importance, access, attitude in clinical practice and perceptions, barriers and facilitators to biosimilars uptake. A descriptive analysis was performed.


Surveys response rate was 100% (hospital pharmacists) and 96% (physicians). We found certain lack of biosimilars knowledge about key aspects including switching, extrapolation, interchangeability or substitution. There was a great variability in the types and brands of biosimilars depending on the hospital. We observed several organization preferences, policies, and practices regarding biosimilars. General perception and attitude to biosimilars was positive. If used, biosimilars were predominantly prescribed in biologic treatment-naive patients (this indication was considered adequate and participants felt comfortable with it). Reluctance to switch in clinical practice was common. The main barriers to biosimilars uptake were the lack of confidence and knowledge. The main facilitators were the development of recommendations from professional associations and societies and the demonstration of interchangeability efficacy. We gathered concerns about biosimilar long term efficacy and safety, lack of real-life data, lack of biosimilars traceability or the risk of biologic reference medicines stock shortages.


Biosimilar education and more evidence filling current gaps might help increase prescriber knowledge, comfort and use of biosimilars.

Keywords : Biosimilar Pharmaceuticals; Drug Substitution; Knowledge; Perception; Surveys and Questionnaires; Variability; Spain.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )